Form 4: Soleno Therapeutics Executive Sells Shares to Cover Tax Obligations

Meredith Manning, Chief Commercial Officer of Soleno Therapeutics, sold shares of common stock on March 27, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On March 27, 2025, Meredith Manning, the Chief Commercial Officer of Soleno Therapeutics, executed multiple transactions involving the company's common stock.
• Manning sold a total of 45,351 shares of common stock at prices ranging from approximately $65.15 to $72.80 per share.
• These sales were primarily to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Additionally, Manning exercised an option to acquire 37,000 shares at a price of $46.31 per share.
• Following these transactions, Manning directly owns 82,351 shares of common stock and holds options for 91,000 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions primarily involve stock sales to cover tax obligations, which is a routine financial activity. The exercise of stock options is a positive sign, but the overall impact is balanced.

Industry Context

Form 4 filings are a routine part of the stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's perspective on the company's stock and future prospects. However, sales to cover tax obligations are common and do not necessarily indicate a negative outlook.

Stakeholder Impact

• The stock sales could have a minor, temporary impact on the stock price, but the overall impact on stakeholders is likely to be minimal.

Key Dates

Keywords

Form 4, Soleno Therapeutics, SLNO, Meredith Manning, Chief Commercial Officer, Stock Sale, Restricted Stock Units, RSUs, Tax Withholding, Option Exercise, Beneficial Ownership